Engineered Stem Cells Provide Cancer-Killing iNKT Cells.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31585091.
- Also identified by DOI 10.1016/j.stem.2019.09.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Invariant natural killer T (iNKT) cells have been tested for their potential use in cancer immune therapy, but their low frequency has limited their use. In this issue, Zhu and colleagues propose to overcome this by engineering hematopoietic stem cells (HSCs) to provide a continual source of iNKT cells. (Zhu et al., 2019).
Medical subject headings
- Natural Killer T-Cells
- Neoplasms